-
February 04, 2013
Merck & Co's fourth-quarter earnings have fallen 7.3%, but new products have helped soften the blow of losing US patent protection on its asthma/allergic rhinitis blockbuster Singulair
Full story
-
October 29, 2012
Merck & Co's third-quarter earnings have edged up 2%, helped by tax gains, as new products helped soften the blow of losing US patent protection on its blockbuster Singulair
Full story
-
July 30, 2012
Merck & Co's second-quarter earnings have fallen 11.4% as a result of acquisition and restructuring charges, but revenues have edged up 1.3%, aided by the diabetes drugs Januvia and Janumet
Full story
-
April 30, 2012
Merck & Co's first-quarter earnings have been boosted by good performances from diabetes drugs Januvia and Janumet, the cholesterol drug Zetia and the cervical cancer vaccine Gardasil
Full story
-
February 03, 2012
Merck & Co's fourth-quarter sales have been boosted by good performances from diabetes drugs Januvia and Janumet and the cervical cancer vaccine Gardasil, but the US giant is expecting a tough 2012
Full story
-
November 25, 2011
The UK government has announced that from next September, it will switch to using Sanofi Pasteur MSD's Gardasil instead of GlaxoSmithKline's Cervarix for its human papillomavirus vaccination programme
Full story
-
October 31, 2011
Merck & Co's third-quarter net income has rocketed thanks to lower charges and strong sales of a number of key drugs, notably the diabetes drugs Januvia and Janumet and the cervical cancer vaccine Gardasil
Full story
-
July 04, 2011
Merck & Co, GlaxoSmithKline and Astellas are among the beneficiaries in the latest list of approvals from Japan's Ministry of Health, Labour and Welfare
Full story
-
June 07, 2011
The tide of bad press the pharmaceutical industry gets has been stemmed a little with the news that some of the sector's big players have cut the price of vaccines for people in poor countries
Full story
-
May 03, 2011
Merck & Co's first quarter net income has more than tripled thanks to lower charges and a striking rise in sales of its diabetes drugs Januvia and Janumet
Full story